Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.

Antiviral therapy - 1 Jan 2008

Borghi Vanni, Puoti Massimo, Mussini Cristina, Bellelli Stefania, Angeletti Claudio, Sabbatini Francesca, Prati Francesca, Cossarizza Andrea, Esposito Roberto

Abstract excerpt

BACKGROUND: Liver steatosis is a common finding in hepatitis C virus (HCV) infection and is associated with an increased progression of the disease. However, HCV genotype 3 steatosis presents a peculiar and virus-induced pathogenesis. We analysed the effect of HIV coinfection and antiretroviral t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to HIV Infections

Share to Logistic Models

Share to Odds Ratio

Share to Risk Factors

Source

Identifiers

PMID: 19195331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19195331-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.PMID 19195331Read ↗

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.Semantic proximity Read ↗

Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.Semantic proximity Read ↗

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.Semantic proximity Read ↗

Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype.Semantic proximity Read ↗

Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.Semantic proximity Read ↗

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.Semantic proximity Read ↗

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.Semantic proximity Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.Semantic proximity Read ↗

Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Semantic proximity Read ↗

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?Semantic proximity Read ↗

Steatosis affects chronic hepatitis C progression in a genotype specific way.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.